

Igni Cognition: clinical trial results (n = 69)

Group taking enhanced the Igniton supplement significantly outperformed placebo:

Cognitive Test	Human Study (after 3 months, n = 69)
Short Term Memory	82% improvement
Operational Memory	43% improvement
Attention Span	84% improvement
Cognitive Efficiency	94% improvement
Quality of Performance	100% improvement



The image shows the cover of a report titled "Report Comparative Study for IgniCogni (improvement of memory, performance, attention, and error reduction) Results before the intake and after the 1st, 2nd and 3rd month of use (January 27- February 28 - March 28 - April 28 2022)". The report is from the Federal Scientific Center of Neurophysiology and Neuropharmacology of the Russian Academy of Sciences, Siberian Branch, Institute of Neurophysiology, Novosibirsk. The cover features the Igni Cognition logo and a list of ingredients including Alpha-Ketoglutarate, Alpha-GABA-GPC, Alpha-Phosphatidylserine, Alpha-Glutathione, L-Theanine, and Creatine. It also includes a list of dietary supplement facts and a warning to keep it out of reach of children.

Experimental Group 1 – 34 people, age 25-70 years (intake initiated on January 27, 2022)
The subjects took the original *Igni Cognition* during the first month, and the new *Igni Cognition* (the same ingredients, with *Igni Alpha GPC* added) during the second and third months.

After the three months study, statistically significant positive changes on all indicators were observed. Specifically the improvements to short-term and operational memory as well as the speed of mental processing were significant.

Comparing the 2nd, 3rd, and 4th test batches (after the 1st, 2nd, and 3rd month of intake), statistically significant positive changes on all indicators were observed.

Experimental Group 2 – additional 15 people, age 26-70 years – intake of new *Igni Cognition* (with *Igni Alpha GPC*) for two months – initiated on February 26, 2022.

All indicators changed positively, not a single indicator demonstrated a negative trend.

Control Group – 20 people, 26-74 years, took a nootropic commercial product (selected by the academic team) without Igniton enhancements.

In the Control Group – comparing results after the 1st, 2nd, and the 3rd month, indicators mostly worsened. The changes overall were not statistically significant.